Understand the source comparison
Best Peptides for Erectile Dysfunction: Mechanism Comparison
The following table summarizes the peptides most studied for erectile dysfunction, organized by primary mechanism of action. Each peptide addresses a distinct failure point in the erectile cascade. Selecting the 'best' peptide depends entirely on where dysfunc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table summarizes the peptides most studied for erectile dysfunction, organized by primary mechanism of action. Each peptide addresses a distinct failure point in the erectile cascade. Selecting the 'best' peptide depends entirely on where dysfunction originates.
- PT-141 (Bremelanotide)
- Central arousal via melanocortin receptor activation. Enhances sexual desire and autonomic arousal independent of peripheral vascular function
- MC3R, MC4R (hypothalamus, limbic system)
- Phase 2B trials show 52% successful intercourse attempts vs 32% placebo in men who failed sildenafil; FDA-approved for female hypoactive sexual desire disorder
- Subcutaneous injection, 1.75mg, 45–60 min onset
- Best for psychogenic ED, SSRI-induced dysfunction, or performance anxiety where vascular capacity is intact but central arousal is impaired
- Melanotan II
- Dual mechanism: central arousal via MC4R plus peripheral smooth muscle relaxation through non-NO pathways
- MC1R, MC3R, MC4R (central and peripheral)
- Animal studies show increased intracavernosal pressure independent of nitric oxide synthase; human data limited to case reports and observational studies
- Subcutaneous injection, 0.5–2mg, 30–90 min onset
- Best for mixed central and peripheral dysfunction; broader receptor activity includes melanogenesis (tanning) and potential nausea at higher doses
- Kisspeptin-10
- Hypothalamic-pituitary-gonadal axis activation. Stimulates endogenous testosterone production by increasing LH pulse frequency
- GPR54/KISS1R (GnRH neurons in hypothalamus)
- Clinical trials show restoration of LH pulsatility and testosterone in hypogonadotropic men; no direct ED trials published
- Intravenous or subcutaneous, short half-life requires frequent dosing or infusion
- Best for ED secondary to low testosterone from hypothalamic suppression (obesity, opioid use, metabolic syndrome); ineffective in primary testicular failure
- VIP (Vasoactive Intestinal Peptide)
- Direct corpus cavernosum smooth muscle relaxation via cAMP elevation. Independent of nitric oxide-cGMP pathway
- VPAC1, VPAC2 (smooth muscle)
- Phase 3 trial of VIP + phentolamine showed 58% success rate vs 71% for alprostadil; effective but not superior to existing intracavernosal agents
- Intracavernosal injection, 10–20 mcg
- Best for men with severe endothelial dysfunction who cannot respond to PDE5 inhibitors; delivery method (penile injection) limits patient acceptance
- Oxytocin
- Central arousal modulation plus peripheral nitric oxide release from endothelial cells and nerve terminals
- Oxytocin receptor (brain, corpus cavernosum endothelium)
- Animal studies show NO release and smooth muscle relaxation; human trials show inconsistent results, possibly due to poor CNS penetration
- Intranasal or subcutaneous, rapid metabolism limits duration
- Limited clinical utility as monotherapy; may have adjunctive role in combination protocols targeting multiple pathways